Ventyx Biosciences’ (VTYX) Market Perform Rating Reiterated at Lifesci Capital

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “market perform” rating reissued by equities research analysts at Lifesci Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $14.00 price objective on the stock. Lifesci Capital’s price objective indicates a potential upside of 1.97% from the company’s current price.

A number of other equities research analysts also recently weighed in on VTYX. HC Wainwright raised shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Canaccord Genuity Group restated a “hold” rating and set a $14.00 price objective (down previously from $16.00) on shares of Ventyx Biosciences in a research report on Thursday. Oppenheimer lifted their price objective on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Finally, Wells Fargo & Company increased their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.67.

Ventyx Biosciences Trading Up 36.6%

VTYX stock opened at $13.73 on Thursday. The firm has a 50 day moving average of $9.05 and a 200-day moving average of $5.14. The firm has a market capitalization of $979.77 million, a P/E ratio of -9.15 and a beta of 1.23. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.13. Sell-side analysts predict that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Activity at Ventyx Biosciences

In other news, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer directly owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. The trade was a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John Nuss sold 12,675 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares of the company’s stock, valued at $3,778,793.32. This trade represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 14.49% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. CWM LLC lifted its stake in shares of Ventyx Biosciences by 7.6% in the 2nd quarter. CWM LLC now owns 57,145 shares of the company’s stock valued at $122,000 after acquiring an additional 4,057 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Ventyx Biosciences by 21.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after purchasing an additional 5,174 shares during the period. Prelude Capital Management LLC lifted its position in Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company’s stock valued at $66,000 after purchasing an additional 5,500 shares during the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Ventyx Biosciences during the second quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Ventyx Biosciences during the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.